Adverse events after protamine administration in patients undergoing cardiopulmonary bypass: Risks and predictors of under-reporting

被引:37
作者
Kimmel, SE
Sekeres, MA
Berlin, JA
Goldberg, LR
Strom, BL
机构
[1] Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA
[3] Hosp Univ Penn, Dept Med, Div Cardiovasc, Philadelphia, PA 19104 USA
[4] Massachusetts Gen Hosp, Dept Med, Cardiac Unit, Boston, MA 02114 USA
关键词
adverse drug reaction reporting systems; pharmacoepidemiology; cohort studies; risk factors; cardiopulmonary bypass; protamines;
D O I
10.1016/S0895-4356(97)00241-2
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
A retrospective cohort study of patients undergoing cardiopulmonary bypass over 2 years at a single hospital was performed to determine the rate and predictors of attributing events to protamine and reporting them to a well-developed, hospital-based adverse drug reaction (ADR) program. Overall, 123 (12.9%) of 952 procedures were associated with an adverse event. Thirteen percent of these events were attributed to protamine in the medical record and 2.4% were reported to the ADR program. Only 19% of events attributed to protamine were reported. Even after excluding events with other measurable etiologies, the incidence of adverse events (2.6%) was still higher than that of attributed (0.8%) or reported (0.3%) events. Events that manifest as pulmonary hypertension occurred sooner after protamine, or were severe were significantly more Likely to be attributed to protamine. These predictors demonstrated similar relationships with the probability of reporting events. Reliance on reporting of adverse events could not only underestimate the risk of these events, but might bias studies by identifying non-representative events. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:1 / 10
页数:10
相关论文
共 27 条
  • [1] Baum C, 1994, PHARMACOEPIDEM DR S, P125
  • [2] COMPARATIVE-STUDY OF PROSPECTIVE SURVEILLANCE AND VOLUNTARY REPORTING IN DETERMINING INCIDENCE OF ADVERSE DRUG-REACTIONS
    BENNETT, BS
    LIPMAN, AG
    [J]. AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1977, 34 (09): : 931 - 936
  • [3] BOSCLAIR MD, 1993, BLOOD, V82, P3350
  • [4] DRUG-INDUCED BLOOD DYSCRASIAS IN SWEDEN
    BOTTIGER, LE
    WESTERHOLM, B
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1973, 3 (5875): : 339 - 343
  • [5] COMPUTERIZED SURVEILLANCE OF ADVERSE DRUG EVENTS IN HOSPITAL PATIENTS
    CLASSEN, DC
    PESTOTNIK, SL
    EVANS, RS
    BURKE, JP
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 266 (20): : 2847 - 2851
  • [6] PLATELET FACTOR-IV EFFICIENTLY REVERSES HEPARIN ANTICOAGULATION IN THE RAT WITHOUT ADVERSE-EFFECTS OF HEPARIN PROTAMINE COMPLEXES
    COOK, JJ
    NIEWIAROWSKI, S
    YAN, ZQ
    SCHAFFER, L
    LU, WQ
    STEWART, GJ
    MOSSER, DM
    MYERS, JA
    MAIONE, TE
    [J]. CIRCULATION, 1992, 85 (03) : 1102 - 1109
  • [7] GOTTSCHLICH GM, 1988, ANN ALLERGY, V61, P277
  • [8] GUPTA SK, 1988, J VASC SURG, V9, P342
  • [9] A NATIONWIDE INVESTIGATION OF A POSSIBLE PROTAMINE DRUG-PRODUCT DEFECT
    HERRERA, CR
    GRASELA, TH
    WALAWANDER, CA
    [J]. ANNALS OF PHARMACOTHERAPY, 1992, 26 (05) : 643 - 644
  • [10] HORROW JC, 1985, ANESTH ANALG, V64, P348